News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387

NanoViricides

NanoViricides CEO Dr Anil Diwan joined Steve Darling from Proactive to share exciting updates on their antiviral drug candidate, NV 387. The drug, developed in response to the COVID-19 pandemic, demonstrated exceptional safety in clinical trials, even at the highest dose levels, with no adverse events reported. The unique mechanism of action involves mimicking a cell membrane, encapsulating and blocking the virus. The clinical trials involved both oral tablets and oral gummies, catering to various age groups, including pediatrics. NV 387 exhibited broad-spectrum activity against multiple strains of coronaviruses, showcasing effectiveness 10 times greater than remdesivir in preclinical studies. Beyond COVID-19, the drug also displayed promising results against respiratory syncytial virus (RSV), offering a potential solution for infants and seniors where existing treatments like ribavirin may be contraindicated due to side effects. Dr Diwan highlighted the drug's versatility, suggesting applications against other respiratory viruses and even biodefense-related infections like smallpox. The ongoing clinical trial progress and positive results position NanoViricides at the forefront of antiviral drug development, marking a significant milestone in their journey from preclinical research since 2005 to clinical trials. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

November 29, 2023 01:32 PM Eastern Standard Time

Video
Article thumbnail News Release

Vivos Therapeutics hits major milestone with FDA clearance for treating severe sleep apnea

Vivos Therapeutics

Vivos Therapeutics CEO Kirk Huntsman joined Steve Darling from Proactive to announce a significant milestone for the company with its first-ever 510(k) clearance from the US Food and Drug Administration (FDA). The clearance is for the treatment of severe obstructive sleep apnea (OSA) in adults using Vivos' removable CARE oral appliances. This clearance covers Vivos' CARE appliances, which include the flagship DNA oral appliance, the mRNA oral appliance, and the mmRNA oral appliance. Vivos is now the first company to receive FDA approval and bring to market a clear alternative treatment for patients with severe OSA, offering an alternative to continuous positive airway pressure (CPAP) therapy or surgical neurostimulation implants. This achievement follows closely on the heels of Vivos' previous FDA 510(k) clearance granted just eleven months ago, allowing the company to treat mild-to-moderate OSA with its DNA oral appliance. This recent clearance marks the first time the FDA has ever granted approval for an oral appliance to treat both moderate and severe OSA in adults aged 18 and older, in combination with positive airway pressure and/or myofunctional therapy as needed. Vivos Therapeutics' dedication to advancing innovative treatments for sleep apnea underscores its commitment to improving the quality of life for individuals suffering from this condition. With this latest clearance, the company is positioned to provide an effective and accessible treatment option for a broader range of OSA patients, offering hope for improved sleep and overall well-being. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

November 29, 2023 01:04 PM Eastern Standard Time

Video
Article thumbnail News Release

Africa CDC and Mastercard Foundation launch phase 2 of the Saving Lives and Livelihoods (SLL) initiative to strengthen Africa’s public health systems

Mastercard Foundation

LUSAKA, ZAMBIA - African Media Agency - 29 November 2023 - The Africa CDC and the Mastercard Foundation have entered a new phase of their partnership on the Saving Lives and Livelihoods initiative in the aftermath of WHO's declaration of the end of COVID-19 pandemic as a public health emergency of international concern. The Saving Lives and Livelihoods initiative, a bold and unprecedented $1.5 billion partnership, was launched in June 2021. This innovative and ground-breaking partnership aimed to purchase COVID-19 vaccines, roll out vaccinations, build the vaccine manufacturing workforce for the continent, and strengthen the Africa CDC to ensure long-term health security for Africa. Unprecedented in scale, speed and inclusion of African organisations, the partnership has contributed to the continent's current vaccination rate of 53 per cent of the target population, up from just 3 per cent at the start of the initiative. The partnership has also trained, equipped, and deployed 38,000 health workers, creating a robust frontline in safeguarding public health locally. It has provided job opportunities for 23,000 individuals and integrated over 600 COVID-19 vaccination centres into healthcare systems. Additionally, this initiative led to the expansion of genomic testing capabilities from seven to 40 laboratories across the continent. The review of Phase 1 of this initiative, among fifteen implementing partners across 29 countries, conducted by Deloitte, indicates that the vast majority of funds disbursed were used effectively and as intended. Likewise, ongoing monitoring by KPMG has confirmed that partners not only showed strength in programmatic results but also improved the institutional capacity for greater sustainability and institutional resilience. "Our Saving Lives and Livelihoods initiative with the Mastercard Foundation has shown the power of respectful and action-oriented partnerships rooted in collaboration, coordination and systems strengthening. The experience and learnings from Phase I will enable us to move with greater speed and scale to deliver with accelerated impact to our member states" said Dr. Jean Kaseya, Director General of the Africa CDC. In its second phase, the partnership will expand its scope and scale, focusing on completing the vaccination of healthcare workers and vulnerable groups, building a robust workforce of community health workers, ensuring pandemic preparedness by bolstering national public health institutions, laboratory capacities, data access and quality, local manufacturing of vaccines, therapeutics and diagnostics, and continuing strengthening of Africa CDC. "While the global pandemic may be declared over, the need to continue investing in our health systems, build our workforce and prepare for future pandemics remains urgent. This partnership will ensure that we have strong health institutions and systems. We aim to enable thousands of young people to build their careers in healthcare and contribute to improving lives in Africa," said Reeta Roy, President, and CEO of the Mastercard Foundation. The Saving Lives and Livelihoods initiative stands out as a testament to the power of African-led health solutions. As it progresses to its next phase, partnerships will continue to play a crucial role in shaping a New Public Health Order for Africa. Africa CDC and the Mastercard Foundation remain committed to improving the health and well-being of all Africans. About the Africa Centres for Disease Control and Prevention (Africa CDC) Africa CDC is a continental autonomous health agency of the African Union established to support public health initiatives of Member States and strengthen the capacity of their public health institutions to detect, prevent, control, and respond quickly and effectively to disease threats. For more information, please visit: http://www.africacdc.org About the Mastercard Foundation The Mastercard Foundation is a registered Canadian charity and one of the largest foundations in the world. It works with visionary organisations to advance education and financial inclusion, enabling young people in Africa and Indigenous youth in Canada to access dignified and fulfilling work. Established in 2006 through the generosity of Mastercard when it became a public company, the Foundation is an independent organisation separate from the company, with offices in Toronto, Kigali, Accra, Nairobi, Kampala, Lagos, Dakar, and Addis Ababa. Its policies, operations, and program decisions are determined by the Foundation's Board of Directors and leadership. For more information on the Foundation, please visit www.mastercardfdn.org. Contact Details Wariko Kabuga-Waita wwaita@mastercardfdn.org

November 29, 2023 12:13 PM Eastern Standard Time

Image
Article thumbnail News Release

ACD/Labs Announces Automation Software to Fast-track Digitalization and AI-Readiness of R&D Laboratories

ACD/Labs

To support ongoing digital transformation in life sciences and chemistry-driven organizations, ACD/Labs has introduced Spectrus Conduit —the first out-of-the-box, low-code/no-code application that connects, designs, and manages automated dataflows from analytical instruments and other data sources. Spectrus Conduit creates standardized, harmonized digital twins of the R&D laboratory, improves collaboration, and supports downstream AI/ML applications. ACD/Labs also announced the expansion of their browser-based Spectrus JS portfolio to proliferate access to cloud-based analytical data management. At BioIT World Europe, ACD/Labs, an informatics company that develops and commercializes software in support of R&D, today announced new applications that will help organizations: Implement automated, extensible analytical data flows from over 150 natively supported instrument formats (NMR, LC/MS, IR, etc.) and other laboratory data sources for improved collaboration and data aggregation. Apply digital chemical intelligence, spectral prediction, and contextual science-based data assembly to produce digital twins of analyses, reducing time-to-market decisions. Facilitate digital knowledge proliferation and accessibility while assuring FAIR and ALCOA+ principles. Accelerate machine learning and data science utilization by simplifying data engineering. ACD/Labs’ Spectrus Platform has helped organizations address their analytical data accessibility challenges for almost thirty years. Decades-long vendor partnerships equip Spectrus Platform users with technique-agnostic, commercial, off-the-shelf support for all major instrument vendor formats. Spectrus offers organizations technologies to support digital transformation (Dx) initiatives—especially those that account for automated data capture, interpretation, and storage of data, with ACD/Labs’ specialty being instrumental analytical chemistry. Recent Spectrus Platform development efforts have focused on the release of an off-the-shelf, low-code/no-code application for the design and management of workflow automation (Spectrus Conduit). In addition, ACD/Labs has continued migrating the capabilities scientists have relied on for decades to browser-based applications. Software in the Spectrus JS family provides on-demand data processing and the facile distribution of data marshaling and management to improve data accessibility. Vice President of Innovation and Informatics Strategy at ACD/Labs, Andrew Anderson, says, “We want to help organizations control the flow of their own instrument-generated data but with the flexibility to adapt such controls without relying on extensive configuration and customization services. Commercial, off-the-shelf capabilities now provided by the Spectrus Platform empower organizations to automate the marshaling, processing, analysis, and proliferation of datasets emanating from their instrument data sources. The application of Spectrus analysis capabilities results in digitally contextualized experimental datasets—digital twins—all without unnecessary manual intervention. Spectrus Conduit not only supports facile, automated, data-driven decision-making for scientists, it also reduces the cost and effort of data science practices. Automated, cross-technique-enabled data science is a significant challenge for the analytical data space today.” “We are building on our legacy of informatics tools to help better address the needs of the scientific community—now and for the digital future,” Anderson continues. “With the introduction of Conduit for automating analytical and instrument workflows, and by continuing the expansion of our browser based Spectrus JS portfolio, we help alleviate software maintenance and support burden on IT teams. We also ensure that your data is not locked into our environment by providing multiple options for export, including JSON export—a necessity when you want to leverage your data for machine learning or AI projects.” To learn more about Spectrus Conduit, Spectrus JS applications, or the Spectrus Platform, visit ACD/Labs at Booth #13 at BioIT World Europe or www.acdlabs.com. About ACD/Labs ACD/Labs is a leading provider of scientific software for R&D. We help customers in >94 countries around the world assemble digitized analytical, structural, and molecular information for effective decision-making, problem solving, and product lifecycle control. Our enterprise technologies enable automation of molecular characterization and facilitate chemically intelligent knowledge management. ACD/Labs provides worldwide sales and support and brings decades of experience and success helping organizations innovate and create efficiencies in their workflows. For more information, please visit www.acdlabs.com. Follow us on Twitter and LinkedIn. Contact Details ACD/Labs Sanji Bhal +1 416-368-3435 media@acdlabs.com Racepoint Global Allison Matthews +1 617-624-3248 rpgacdlabs@racepointglobal.com Company Website https://www.acdlabs.com/

November 29, 2023 04:00 AM Eastern Standard Time

Article thumbnail News Release

Melissa & Doug Toys Co-founder Introduces Lifelines, Well Being Tools That Activate Senses, Promote Stress Relief

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/ytMbkUGV8kg It’s no secret that stress relief can get stressful for many people. Science tells us that 80% of stress relief starts in your body, not your brain. What if there was a way to bring stress relief to your fingertips with a science-backed collection of physical tools designed to activate the nervous system's calming response. Melissa Bernstein, the creative Founder behind Melissa & Doug Toys, is introducing her newest venture, Lifelines, a collection of Sensory Immersion™ tools that activate the body's natural stress relievers, your senses. For more than 30 years, Melissa conceived over 10,000 toys designed to unleash children's imagination, but behind-the-scenes she hid a lifelong struggle with anxiety, depression and stress. When she immersed her senses - she was able to break the cycle of rumination and experience the present moment in totality. That is the backstory and inspiration for Lifelines. Lifelines will offer a comprehensive suite of Sensory Immersion tools across all six senses. The first collection is focused on aroma, a powerful and science-backed category Melissa felt lacked innovation. The collection includes 45 products with 16 patents pending, spanning portable fidget tools, sensory writing, innovative diffusers, and essential oil blends. There are over 100 new products in development, including meditative art activities for adults and multi-sensorial sound and sight devices. Lifelines Grounding Stones are patent-pending handheld diffusers designed for touch, combining the power of scent with fidgeting. Fidgeting has been scientifically proven to reduce stress and improve focus. The six unique and touchable designs feature an irresistible swivel and fit perfectly in the palm, for stress relief anytime, anywhere. Lifelines sensory writing tools inspire focus and spark creativity. The Scented Colored Pencils elevate any writing experience. And the Pen Diffuser combines an innovative writing tool with four distinct aromas dispensed at your fingertips. Tactile Sensory Journals feature covers made for touch, with soothing embossed patterns inside to keep your ideas flowing. Lifelines immersive diffusers pair with any of their 20 essential oil blends to activate smell, touch, and sight. The Waves Ultrasonic Diffuser combines breathtaking scents, colorful lights, and cascading mist inspired by the ocean's tides. The Shower Diffuser and Bath Diffuser turn any bathroom into a spa-like getaway. The portable and lightweight Everyday Diffuser fits perfectly into small spaces like a drawer, car or bag with no batteries or cords required. And then there are Lifelines Essential Oil Blends, thoughtfully crafted aromas inspired by nature and curated by Melissa. This includes more than 20 different blends across five intoxicating scent families and four well- being goals: Energy, Calm, Focus, and Joy. Blends are made from naturally derived, sustainably sourced botanicals, free from parabens and dyes, and blended in the USA. All oils come with Lifelines' patent-pending Precision Pump™ for a mess-free application that dispenses the perfect amount of oil every time. Lifelines products are affordably priced from $5.99-$29.99 and available at popular retailers nationwide including Target. For more information, visit Lifelines.com About Lifelines Founded in 2022, Lifelines, is a collection of Sensory Immersion™ tools that activate the body's natural stress relievers, the senses. From the creative mind of toy maker and play expert, Melissa Bernstein, Lifelines established a new category of adult well-being products that are affordably priced and accessible at major retailers nationwide. For more information visit www.Lifelines.com. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 28, 2023 03:00 PM Eastern Standard Time

Video
Article thumbnail News Release

Syra Health Corp announces company has launched a new digital health product SyraBot

Syra Health Corp.

Syra Health Corp Executive Chairman and President Sandeep Allam joined Steve Darling from Proactive to share the introduction of SyraBot. This innovation is a new offering from the company's Digital Health business unit. SyraBot represents a significant leap in Syra Health's commitment to enhancing user engagement through technology. It is an AI-backed chatbot designed to be human-centric, providing immediate and conversational style responses to users' inquiries on healthcare organizations' websites. The chatbot is engineered to ensure that information is readily accessible around the clock, every day of the week. SyraBot stands out due to its inclusivity, supporting over 200 languages and dialects, and its accessibility, ensuring that the information is understandable even at a fifth-grade reading level. Furthermore, Syra Health has tailored SyraBot to cater to three distinct sectors in the healthcare industry: payers, providers, and state governments, demonstrating the company's strategic approach to meeting diverse needs within the healthcare ecosystem. In addition to the launch of SyraBot, Allam discussed Syra Health's financial milestones, highlighting the company's performance in the third quarter of 2023. The company observed a revenue of $1.58 million, marking a 4% increase from the $1.51 million reported in the third quarter of the previous year. Notably, the Population Health and Health Education segments, driven by epidemiology and reporting services, experienced a substantial revenue surge, with a reported 400% growth. This financial uptick underscores the company's progress and the burgeoning demand for its specialized services in the healthcare domain. Contact Details Proactive United States Proactive United States +1 347-449-0879 action@proactiveinvestors.com

November 28, 2023 09:05 AM Eastern Standard Time

Video
Article thumbnail News Release

Introducing Doceree Insights: Revolutionizing Healthcare Marketing Analytics with the Power of AI

Doceree Inc

Today, Doceree, the leading global platform building unprecedented solutions for healthcare professional (HCP) messaging, proudly unveils its new groundbreaking offering – Insights. Inspired by tools like ChatGPT, this innovative solution transforms the way healthcare marketers access and interpret data. As the latest addition to the suite of AI-powered tools on the platform, Insights empowers healthcare marketers with a game-changing approach to analytics, making it easier than ever to unravel crucial business insights from your marketing campaigns. Healthcare marketers often know the business questions they need answered, but don’t always know what data and analytics will help them find those answers. At the heart of Insights is the ability for marketers to pose those questions directly to the platform, and in return, Insights provides data-driven answers in the form of interactive, exportable data visualizations. In an industry marked by evolving trends and ever-increasing demands, healthcare marketers face the challenge of understanding their campaign performance and making data-driven decisions. To address this need, Doceree has developed Insights, a ChatGPT-style tool designed to simplify the analytics process with on-demand access to vital information quickly and effortlessly. With Insights, marketers can explore all their campaign data – including physician and provider level data (PLD). By leveraging Doceree’s proprietary HCP identity-resolution technology Espyian TM, Insights can answer detailed questions about campaign performance at the individual level. Data and analytics that were previously fragmented and complex, are now easily accessible on-demand with this innovative tool. Using artificial intelligence, Insights harnesses the power of natural language processing (NLP) to interpret and understand the marketer’s question and get them the answer they seek. Insights eliminates the need to sift through static charts and predefined dashboards that often hinder quick and efficient data exploration. This interactive, AI-powered tool also allows users to export and incorporate the right data and visualizations into their own branded presentations, making it even easier for marketers to tell their story with data. “ Doceree is committed to finding the bottlenecks in pharma messaging and bridging them with its AI-powered, category-focused platform and end-to-end solutions that allow pharma marketers to activate top-performing campaigns, while also effectively tracking their KPIs. With our new offering- Insights, we are set to revolutionize healthcare marketing analytics, making data-driven decisions for pharma marketers, as easy as asking a question,” said Harshit Jain MD, Founder & Global CEO at Doceree. In the competitive landscape of healthcare marketing analytics, Insights stands out as a powerful tool that simplifies the process of understanding campaign performance. By allowing customers to pose questions directly to the platform, they can quickly identify and access the precise data they require, without the need for advanced analytics skills. Key Benefits of Doceree Insights: Intuitive & AI-Powered | Helps find actionable insights and answers to questions quickly, easily, without the need for advanced analytical skills Exportable | Enables pharma marketers to tell their story their way, by allowing incorporation of the right data and visualizations into branded presentations and other materials with the ‘Export’ function On-Demand | Eliminates the frustration and inflexibility of static charts and predefined dashboards; marketers can simply ask questions and Insights will return the precise data in the form of interactive visualizations. Doceree Insights is available for healthcare marketers across the globe. For more information about Insights and how it can transform healthcare marketing analytics, please visit https://doceree.com/us/doceree-insights/ or contact partner@doceree.com. About Doceree Doceree is a global platform building unique solutions for healthcare professional (HCP) programmatic messaging with proprietary data tools. It facilitates messaging between life sciences brands and HCPs through an extensive global network of digital endemic and point-of-care platforms to programmatically deliver personalized communications to HCPs at scale. To learn more, visit doceree.com. Contact Details Priyanka Bhasin +91 78387 03702 priyanka.bhasin@doceree.com Tanya Singh +91 70420 89805 tanya.singh@doceree.com Company Website https://doceree.com/us/

November 28, 2023 08:30 AM Eastern Standard Time

Image
Article thumbnail News Release

Doceree introduces AI-powered Insights to revolutionize Analytics in Pharma Marketing

Doceree Inc

Doceree, the leading global platform building unprecedented solutions for healthcare professional (HCP) messaging, today unveiled its groundbreaking new offering – Insights. Inspired by tools like ChatGPT, this innovative solution is set to transform the way pharma marketers access and interpret data. As the latest addition to the suite of AI-powered tools on the platform, Insights will empower healthcare marketers with a game-changing approach to analytics, making it easier than ever to unravel crucial business insights from marketing campaigns. In an industry marked by evolving trends and ever-increasing demands, pharma marketers face the challenge of understanding their campaign performance and making data-driven decisions. They often know the business questions they need answered, but don’t always know what data and analytics will help them find those answers. To address this need, Doceree developed Insights to simplify the analytics process with on-demand access to vital information quickly and effortlessly. With Insights, pharma marketers can explore all their campaign data by simply posing campaign related questions directly to the platform and receive data-driven answers in the form of interactive, exportable data visualizations. Leveraging Doceree’s proprietary HCP identity-resolution technology Espyian TM, Insights is designed to make data and analytics easily accessible and on-demand, that was previously fragmented and complex. Using artificial intelligence, Insights harnesses the power of natural language processing (NLP) to interpret and understand pharma marketers’ questions and get them the answers they seek. Insights eliminates the need to sift through static charts and predefined dashboards that often hinder quick and efficient data exploration. The interactive, AI-powered tool also allows users to export and incorporate the right data and visualizations into their own branded presentations, making it easier for marketers to tell their story with data. “ Doceree is committed to finding the bottlenecks in pharma messaging and bridging them with its AI-powered, category-focused platform and end-to-end solutions that allow pharma marketers to activate top-performing campaigns, while also effectively tracking their KPIs. With our new offering- Insights, we are set to revolutionize healthcare marketing analytics, making data-driven decisions for pharma marketers, as easy as asking a question,” said Harshit Jain MD, Founder & Global CEO at Doceree. In the competitive landscape of healthcare marketing analytics, Insights stands out as a powerful tool that simplifies the process of understanding campaign performance. By allowing customers to pose questions directly to the platform, they can quickly identify and access the precise data they require, without the need for advanced analytics skills. Key Benefits of Doceree Insights: Intuitive & AI-Powered | Helps find actionable insights and answers to questions quickly, easily, without the need for advanced analytical skills Exportable | Enables pharma marketers to tell their story their way, by allowing incorporation of the right data and visualizations into branded presentations and other materials with the ‘Export’ function On-Demand | Eliminates the frustration and inflexibility of static charts and predefined dashboards; marketers can simply ask questions and Insights will return the precise data in the form of interactive visualizations. Doceree Insights is available for healthcare marketers across the globe. For more information about Insights and how it can transform healthcare marketing analytics, please visit https://doceree.com/uk/doceree-insights/ or contact partner@doceree.com. About Doceree Doceree, the world's first global network of physician-only platforms, offers a cutting-edge solution to programmatically reach HCPs where they consume information in their professional mindset, including medical journals, education platforms, and physician networks. Their proprietary physician identity resolution technology, ESPYIANTM, allows brands to showcase the right information to the right physician at the most opportune moments based on their specialty, location, and professional interests. To learn more, visit https://doceree.com/uk/ Contact Details Priyanka Bhasin +91 78387 03702 priyanka.bhasin@doceree.com Tanya Singh +91 70420 89805 tanya.singh@doceree.com Company Website https://doceree.com/uk/

November 28, 2023 08:00 AM Eastern Standard Time

Image
Article thumbnail News Release

Creo Medical Group reveals good growth prospects at Capital Markets Day - Proactive Research Analyst

Creo Medical Group PLC

Creo Medical Group PLC (AIM:CREO), an innovative UK-based medical technology company, recently showcased significant advancements during their Capital Markets Day, as highlighted by Proactive Research Analyst John Savin in his latest research note. The primary focus was on Creo's new version of their Speedboat product, Speedboat UltraSlim, now compatible with all endoscopy systems worldwide, which marks a major leap in bowel surgery technology for removing cancerous and precancerous polyps. This miniaturization, integrating multiple surgical functions into a 2.8 mm diameter device, signifies Creo's technological prowess and opens a broader market reach. Another critical development is Creo's growing collaboration with robotic surgery companies, notably with Intuitive, the world's largest robotic surgery company. Creo's technology, particularly in coagulation, is seen as pivotal for these partnerships. The company is expected to earn royalties from its technological contributions, enhancing its revenue streams. A notable product in this regard is the SpydrBlade, a miniaturized tool with dual cutting and coagulation capabilities, currently awaiting regulatory approvals. Creo's innovations also address the need for specialized training for surgeons and endoscopists, underscoring the importance of their products in delicate procedures like removing oesophageal cancer. The company's approach involves establishing centers of excellence to concentrate expertise and training, a strategy likely to boost sales and market presence in the UK, US, and Asia Pacific. Financially, Creo is well-positioned, having raised significant capital in March 2023 and expecting to be EBITDA positive by 2025. This financial stability supports their ambitious sales, marketing, and product development plans. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

November 27, 2023 06:55 AM Eastern Standard Time

Video
1 ... 7172737475 ... 302